HEARING

Assessing the Impact of a Safe and Equitable Biosimilar Policy in the United States

Subcommittee on Health
Wednesday, May 2, 2007, 10:00 a.m.
2123 Rayburn House Office Building

Hearing Webcast

(Any use of this recording is subject to Rule XI, 4 of the House of Representatives. See text of Rule XI, 4 as posted by the House Committee on Rules.)

Connect to the Archived Video Webcast of this Hearing (100 kbps) or Download

Windows Media Player is required for Committee Webcasts.

Witness List & Prepared Testimony (pdf files)

Panel I
Janet Woodcock, M.D. Deputy Commissioner and Chief Medical Officer Food and Drug Administration 5600 Fishers Lane Rockville, MD 20857
Panel II
Geoffrey Allan, Ph.D. President, CEO, Chairman of the Board Insmed Incorporated 8720 Stony Point Parkway Suite 200 Richmond, VA 23235	David Schenkein, M.D. Vice President Clinical Hematology/Oncology Genentech, Inc. 1 DNA Way Mailstop 444B South San Francisco, CA 94080
Bruce Downey, J.D. Chairman of the Board Generic Pharmaceutical Association Chairman and CEO Barr Pharmaceuticals, Inc. 400 Chestnut Ridge Road Woodcliff Lake, NJ 07677	William Schwieterman, M.D. Tekgenics, Inc. 3901 Point Road Mobile, AL 36619
Ms. Ruth Hoffman Executive Director The Candlelighters Childhood Cancer Foundation 3910 Warner Street Kensington, MD 20895-0498	Ed Weisbart, M.D. Chief Medical Officer Medical Affairs Express Scripts, Inc. 13900 Riverport Drive Maryland Heights, MO 63042
Richard F. Kingham, J.D. Partner Covington & Burling 1201 Pennsylvania Avenue, NW Washington, DC 20004

Hearing Transcript

Not available at this time. The printed hearing should be available within 90-120 days of the conclusion of the hearing. When available, the text of the printed hearing may be viewed at the U.S. Government Printing Office Web site.

View the committee's latest events

November 2009

Su	Mo	Tu	We	Th	Fr	Sa
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30